{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '1.2.', 'Clinical Study Protocol Agreement', 'Protocol No:', 'BCX7353-302', 'Protocol Title:', 'A Phase 3, randomized, double-blind, placebo-controlled, parallel group study', 'to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral', 'treatment for the prevention of attacks in subjects with hereditary angioedema', 'Date:', 'Version 4.0 (United States): 10 February 2020', 'I have carefully read this protocol and agree that it contains all of the necessary information', 'required to conduct this study. I agree to conduct this study as described and according to the', 'Declaration of Helsinki, International Council for Harmonisation guidelines for Good Clinical', 'Practices, and all applicable regulatory requirements.', \"Investigator's Signature\", 'Date', 'Name (Print)', '4']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '2.', 'SYNOPSIS', 'Name of Sponsor/Company:', 'BioCryst Pharmaceuticals, Inc.', 'Name of Investigational Product:', 'BCX7353', 'Name of Active Ingredient:', '-1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-', '  fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide', 'Title of Study:', 'A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy', 'and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in', 'subjects with hereditary angioedema (Study BCX7353-302)', 'Study centers: Multiple study centers in North America and Europe', 'Principal Investigator: Bruce Zuraw, MD', 'Enrollment period (months): Approximately 9 months', 'Phase of development: 3', 'Part 1 Primary Objective:', 'To determine the efficacy of prophylactic BCX7353 110 mg and 150 mg administered', 'once daily (QD) for 24 weeks compared to placebo in subjects with hereditary', 'angioedema (HAE)', 'Part 1 Secondary Objectives:', 'To assess the safety and tolerability of BCX7353 110 mg and 150 mg administered QD', 'for 24 weeks', 'To assess the effects of BCX7353 on HAE disease activity and HAE attack', 'characteristics', 'To evaluate the effects of BCX7353 on quality of life (QoL)', 'To characterize the pharmacodynamic (PD) effects of BCX7353', 'Part 1 Primary Efficacy Endpoint:', 'The rate of investigator-confirmed HAE attacks during dosing in the entire 24-week', 'treatment period', 'Part 1 Secondary Efficacy Endpoints:', 'Change from baseline in Angioedema Quality of Life (AE-QoL) questionnaire at', 'Week 24 (total score)', 'Number and proportion of days with angioedema symptoms through 24 weeks', 'Rate of investigator-confirmed HAE attacks during dosing in the effective treatment', 'period (beginning on Day 8 through 24 weeks)', '5']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'Part 1 Exploratory Efficacy Endpoints:', 'Number and proportion of subjects with no attacks over 24 weeks', 'Use of HAE attack medications over 24 weeks', 'The proportion of responders to study drug, defined as at least a 50% relative reduction in', 'the rate of investigator-confirmed HAE attacks during treatment compared with the', 'baseline attack rate', 'Part 1 Safety Endpoints:', 'Number and proportion of subjects with a treatment-emergent adverse event (TEAE)', 'Number and proportion of subjects who discontinue due to a TEAE', 'Number and proportion of subjects who experience a treatment-emergent serious adverse', 'event (TESAE)', 'Number and proportion of subjects who experience a Grade 3 or 4 TEAE', 'Number and proportion of subjects who experience a treatment-emergent Grade 3 or 4', 'laboratory abnormality', 'Part 1 Health Outcome Endpoints:', 'EuroQoL 5-dimensional, 5-level questionnaire (EQ-5D-5L) scores', 'Treatment Satisfaction Questionnaire for Medication (TSQM) scores', 'Work productivity and activity impairment questionnaire (WPAI) scores', 'Part 2 Primary Objective:', 'To evaluate the long-term safety and tolerability of BCX7353 110 mg and 150 mg', 'administered QD over a 24- to 48-week administration period in subjects with HAE', 'Part 2 Secondary Objectives:', 'To assess the effectiveness (ie, HAE attack frequency over time) of BCX7353 over', 'a', '24- to 48-week administration period', 'To evaluate QoL and HAE disease activity of BCX7353 over a 24- to 48-week', 'administration period', 'To evaluate subject satisfaction with BCX7353 over a 24- to 48-week administration', 'period', 'Part 2 Primary Endpoints:', 'Number and proportion of subjects with a TEAE', 'Number and proportion of subjects who discontinue due to a TEAE', 'Number and proportion of subjects who experience a TESAE', 'Number and proportion of subjects who experience a Grade 3 or 4 TEAE', '6']\n\n###\n\n", "completion": "END"}